Kiniksa Pharmaceuticals International, plc (KNSA) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day and thank you for standing by. Welcome to the Connexa Pharmaceuticals first quarter 2026 earnings conference call. At this time, all participants are in listen-only mode. After the speaker's presentation, there'll be a question and answer session. To ask a question during the session, you'll need to press star 1-1 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 1-1 again. Please be advised, today's conference is being recorded. I would now like to end the conference over to your speaker today. Jonathan Kirshenbaum, Investor Relations, please go ahead. Thank you, Operator. Good morning, everyone, and thank you for joining Connexa's call to discuss our first quarter 2026 financial results and recent portfolio execution. A press release highlighting these results can be found on our website under the Investors section. As for the agenda, our Chief Executive Officer, Sanj K. Patel, will start with an introduction. From there, Ross Mote, our Chief Operating Officer, will provide an update on ARC List commercial execution. Then, Connexa's Chief Medical Officer, Dr. John Paolini, will review our KPL 387 development program and the ongoing Phase 2-3 clinical trial in recurrent pericarditis. After that, Mark Rogozin, our Chief Financial Officer, will review our first quarter of 2026 financial results. And finally, Sanj will share closing remarks and kick off the Q&A session, for which Evan Tesari, our Chief Strategy Officer, will also be on the line. Before getting started, please note that we will be making forward-looking statements today that are subject to risks and uncertainties that may cause actual results to differ materially from such statements. A review of these statement...